Invex Therapeutics (ASX:IXC) Stock Takes a Hit — Here’s Why

Sonal Goyal

27 October 2026 04:27 PM AEDT

Invex Therapeutics (ASX:IXC) Stock Takes a Hit — Here’s Why

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Invex Therapeutics shares traded at $0.10, down 16.67%, during the 27 October 2026 trading session.
Invex agreed to acquire 100% of Rekover Therapeutics for 45,000,000 shares and 91,250,000 performance rights.
Placements of $10 million at $0.08 per share will fund the REVIVE Phase 2a study and Exenatide development.

Shares in Invex Therapeutics Ltd (ASX:IXC) were trading at $0.10, down 16.67%, during the 27 October 2026 trading session, while the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Invex Therapeutics is a biopharmaceutical company developing Exenatide for neurological conditions related to raised intracranial pressure. The company’s most recent update, dated 26 October 2026, covered a binding share sale and purchase agreement and Capital raising.

Rekover Acquisition (26 October 2026)

In its release dated 26 October 2026, Invex said it signed a binding agreement to acquire 100% of Rekover Therapeutics Limited, a New Zealand company repurposing nalfurafine for demyelinating diseases, including chronic optic neuropathy in patients with multiple sclerosis. Rekover designed REVIVE, a Phase 2a randomised, double blind, placebo controlled study in relapsing remitting multiple sclerosis.

Consideration is 45,000,000 shares and 91,250,000 performance rights in three classes that vest on milestones tied to the REVIVE study and the regulatory pathway. No cash consideration is payable.

Placements and Conditions

Invex received firm commitments for a preliminary Placement of 11,250,000 shares at $0.08 to raise $900,000, and will undertake a further placement of 113,750,000 shares at $0.08 to raise $9,100,000, subject to Shareholder approval. Together they raise $10 million before costs, applied mainly to the REVIVE study and Exenatide development.

Completion of the acquisition is subject to conditions including shareholder approval, an Independent Expert’s Report and Listing Rule requirements. A general meeting is expected in late November or early December 2026.

Sector Context

The broader market was higher during the session, with the S&P/ASX 200 index was at 8,852.80, up 0.49% (42.90 points), at 3:40 pm GMT+11. Biotechnology and specialty pharmaceutical companies report progress through regulatory meetings, clinical studies, licensing and capital raisings.

Invex Therapeutics shares were trading at $0.10, down 16.67%, against a benchmark gain of 0.49%, a gap of 17.16 percentage points. The figures are session data recorded while the market was open and can change before the market finishes trading.

Risks

The acquisition and the larger placement depend on shareholder approval and an independent expert’s report. The placement price of $0.08 is below the session’s trading price, and the acquisition adds a Phase 2a study that has not yet been run.

What Lies Ahead

The release points to the general meeting expected in late November or early December 2026, completion of the acquisition and the start of the REVIVE study.

Wrapping Up

Invex shares fell during the session. The company’s latest update describes an acquisition and raising that remain subject to shareholder approval.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.